You are invited to attend an expert-led panel meeting to discuss the importance of a risk based approach to managing people with type 2 diabetes and the interrelated complications.

  • Dr Kean-Seng Lim

    Dr Lim is a General Practitioner and GP Principal in a small group practice in Mt Druitt, the Immediate Past President of AMA (NSW), and Co-Founder of CareMonitor, a Digital Shared Care and Patient Provider Partnership Platform. He is a past Board member of Western Sydney PHN and current Clinical Council member. In 2015 he was awarded the RACGP General Practitioner of the Year award. He has previously served on the RACGP Faculty Board and Wentwest Board. Among other things, he has been a Clinical Lead with the National E-Health Transition Authority is one of the developers of the schools based obesity prevention and lifestyle education program - SALSA. He currently serves on several advisory groups including the PIP-QI Data Governance Group, as Co-Lead of NSW Health Primary Care Communities of Practice, and Co-Chair of the Western Sydney Urgent Care Services Development Subcommittee. He has been heavily engaged in the Western Sydney PCMH implementation project, and as a member of the Wentwest Clinical leaders group. He is a consultant and trainer with the Health Care Homes Training team, and has delivered educational events for PHN’s across the country on eHealth and PCMH implementation.
  • Dr Brendan McQuillan

    Dr McQuillan is currently Dean and Head of the Medical School at the University of WA. He is a Cardiologist and Director of Echocardiography in the Department of Cardiovascular Medicine at Sir Charles Gairdner Hospital (SCGH). Following completion of his PhD in vascular biology at the Heart Research Institute of WA, he undertook Postdoctoral research at Harvard University and completed a Fellowship in Echocardiography at the Massachusetts General Hospital, Boston, USA. He has led and supervised clinical research in the Department of Cardiovascular Medicine at SCGH since 2004. He has been the supervisor of advanced trainees, and basic physician trainees throughout this time and served as the Director of Clinical Training for Interns and Resident Medical Officers at SCGH for six years. He has been nominated for teaching awards at the University of Western Australia and SCGH. He serves on the Cardiac Society of Australia and New Zealand Quality Standards Committee and was the Convenor of the 2017 CSNAZ Annual Scientific Meeting. He has twenty-five years of clinical experience in Cardiovascular medicine, which has stimulated ongoing interest in a range of research areas aimed at improving clinical outcomes through implementation of research findings.
  • Prof Michael d’Emden

    Prof Michael d’Emden graduated from University of Tasmania in 1978. He was a resident and registrar at the Princess Alexandra Hospital in Brisbane before moving to Royal Melbourne Hospital in 1983. He obtained his fellowship in 1985, completed a PhD at University of Melbourne in 1988 before doing further studies at the University of Iowa.
    He is now the Director of the Department of Endocrinology and Diabetes, Royal Brisbane and Women’s Hospital (RBWH), a Clinical Associate Professor of the University of Queensland and was the vice president of the Australian Diabetes Society 2012-2014. His major clinical interests are the association of diabetes with cardiovascular disease, and lipid metabolism. He serves on many national advisory boards as well as having been a member of the International Management committees of the FIELD, ASPEN and TNT studies. He heads an active clinical research unit at the RBWH and was the principle Australian investigator of the EMPA-REG and DECLARE studies and several other SGLT2i studies.
  • Dr Gary Deed

    Dr Gary Deed is a QLD GP with a passionate interest in promoting quality patient care of diabetes in general practice through education, development of resources including guidelines, national and state resource/policy development , conducting research and strategic collaboration. He has an interest in fatigue disorders and particularly sleep dysfunction.
By continuing to use this website, you consent to the terms of Webstream Communication's Privacy Policy.

This webcast has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. Attendance at AstraZeneca educational meetings is by invitation only and limited to registered healthcare professionals. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support.

PRIVACY STATEMENT: Your personal information ("Information") will be collected and used by AstraZeneca Pty Ltd ("AstraZeneca") for the purpose of administration of the webcast, for follow-up purposes and for any other purpose described in AstraZeneca's Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/service providers),some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy at for more information about how your Information is handled and how you may seek to access or correct your Information, or submit a privacy complaint. AstraZeneca's address is 66 Talavera Road, Macquarie Park, NSW, 2113. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. For Medical Information enquiries: 1800 805 342 or To report an adverse event: 1800 805 342 or via